Last updated: July 22, 2026
Neurocrine Biosciences v. Lupin (1:22-cv-01061): Litigation Summary, Claims at Issue, and Generic-Entry Impact
Neurocrine Biosciences, Inc. v. Lupin Limited, Case No. 1:22-cv-01061 (D. Del.), is a patent infringement action filed in the context of ANDA-driven generic entry challenging Neurocrine’s branded product(s). The case is filed under the U.S. Hatch-Waxman framework, with the dispute focused on whether Lupin’s proposed generic product infringes one or more Orange Book-listed patents tied to Neurocrine’s NDA. The litigation posture affects Paragraph IV leverage, potential 30-month stay timing, and whether Lupin can launch at risk or must seek a later settlement/authorization.
This summary and analysis is limited to the litigation caption provided. No patent numbers, asserted claims, listed drug, or docket milestones are included in the prompt, so a complete claim-level and timing-level analysis cannot be produced.
What claims and patents are at issue in Neurocrine v. Lupin Limited (1:22-cv-01061)?
A claim-level analysis requires the docket’s asserted patent list (Orange Book identifiers, patent numbers, claim charts/pleadings, and infringement theories). The prompt provides only the case number and parties, with no asserted patents or product identification.
What is the asserted Orange Book estate (patents-in-suit)
Not provided.
What infringement theories are typically pleaded in this case
Not provided (cannot map to specific patents without docket/complaint content).
When was the case filed, and what does the procedural timeline imply for a generic launch?
The case number indicates filing in 2022, but the specific filing date, service dates, and Markman schedule are not provided. Without docket dates (complaint filing, answer, Rule 16 scheduling order, claim construction, summary judgment, trial date, and any stay/consent orders), launch impact cannot be quantified.
Does this litigation trigger a Paragraph IV 30-month stay
Not provided.
Is the case stayed or consolidated with related actions
Not provided.
How does Neurocrine’s patent enforcement strategy in this case compare with other neuroendocrine product estates?
Neurocrine’s enforcement typically mixes:
- composition/polymorph formulation protection,
- method-of-use claims (including dosing paradigms),
- and manufacturing or release-control claims depending on the platform (oral small molecules vs. depot formulations).
This cannot be mapped to the specific patent portfolio in 1:22-cv-01061 without the asserted patent numbers and the branded reference product.
What settlement terms or licensing outcomes are possible in Neurocrine v. Lupin Limited?
Settlement outcomes in Hatch-Waxman often include:
- stipulations of non-infringement or invalidity findings,
- launch date carve-outs tied to patent expiry,
- shared-license structures, or
- payment-for-delay style terms (which may be publicly disclosed only in limited docket extracts).
No settlement status or terms are included in the prompt, so no actionable assessment can be made.
What is the litigation posture right now (motions, Markman, expert discovery, trial readiness)?
Current status requires docket pulls:
- motion to dismiss,
- claim construction briefing and rulings,
- preliminary injunction requests,
- summary judgment motions,
- trial scheduling.
Not provided.
What is the generic-entry risk profile for Lupin based on this litigation?
Risk depends on:
- whether the asserted claims survive early dispositive motions,
- claim construction outcomes (especially for formulation or method-of-use),
- the strength of obviousness/invalidity positions under 35 U.S.C. §§ 102/103/112 and any § 101 contentions,
- and whether any noninfringement design-around is feasible.
Not provided (no patents or claim scope).
What is the Orange Book status of Neurocrine’s asserted patents in this matter?
Orange Book status is patent-number specific. The prompt lacks:
- the NDA reference product,
- Orange Book listings,
- and expiration/exclusivity dates.
Not provided.
Table: Key Facts Needed for an Actionable Patent-Litigation Analysis (Not Present in the Prompt)
| Category |
Needed to analyze |
Included in prompt |
| Asserted patents (numbers) |
Which Orange Book patents are in-suit |
No |
| Branded reference product |
Correct drug and formulation platform |
No |
| ANDA number / Paragraph IV notice |
Identify filing and statutory posture |
No |
| Complaint filing date |
Compute schedule and 30-month stay linkage |
No |
| Docket milestones |
Markman, summary judgment, trial |
No |
| Claim construction results |
Maps directly to infringement likelihood |
No |
| Settlement status |
Launch timing and carve-outs |
No |
| Injunctive relief requests |
Preliminary injunction risk |
No |
Key Takeaways
- No patent-level litigation analysis is possible from the provided caption alone because the asserted patent list, the reference NDA product, and the procedural timeline are not included.
- A decision-grade view of generic launch timing, risk at each litigation stage, and expected settlement leverage requires docket and pleadings content that is not present in the prompt.
FAQs
- Does 1:22-cv-01061 involve Paragraph IV validity challenges or only infringement?
- Which Orange Book patents were asserted by Neurocrine in the case?
- What is the earliest potential generic launch date if Lupin prevails in 1:22-cv-01061?
- Is the case tied to a specific Neurocrine NDA and which dosage form is implicated?
- Have there been claim construction rulings that narrowed infringement theories in this matter?
References
- Case caption: Neurocrine Biosciences, Inc. v. Lupin Limited, 1:22-cv-01061 (D. Del.).
